Highlights•An unprecedented number of peptide therapeutics have recently been
approved.•Clinical pipeline analysis reveals an emphasis on peptides with enhanced …

ABSTRACT Introduction: Community-associated MRSA (CA-MRSA) represents a global
epidemic which beautifully encapsulates the fascinating ability of bacterial organisms to …

There has been a welcome increase in the number of agents available for the treatment of
methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin remains an acceptable …

Oritavancin is a long-acting lipoglycopeptide with in vitro activity against Gram-positive
pathogens, as well as good bactericidal activity and sterilisation ability in biofilm. It has been …

Several new MRSA-active agents are now approved for use, although much of the data is
derived from treatment of acute bacterial skin and skin structure infections or pneumonia …

Oritavancin (ORI) is a semisynthetic lipoglycopeptide approved as a single 1200 mg dose
intravenous infusion for the treatment of acute bacterial skin and skin structure infections …

Many approaches are used to discover new antibiotic compounds, one of the most
widespread being the chemical modification of known antibiotics. This type of discovery has …

Gram positive pathogens are a significant cause of healthcare-associated infections, with
Staphylococci and Enterococci being the most prevalent ones. Vancomycin, a last resort …

Natural products have been a major source of anti-infective drugs for many decades. With
urgent need for new antibacterial agents to combat drug-resistant bacteria, the investigation …

The in vitro activity of oritavancin was assessed against 44,715 gram-positive pathogens
causing infections in European and United States (US) hospitals (2010–2014). There were …